Zenas BioPharma, Inc. Common Stock (ZBIO) support and resistance · rev $10.0M
Zenas BioPharma, Inc. Common Stock (ZBIO) is a biotechnology company listed on US.
This page maps Zenas BioPharma, Inc. Common Stock (ZBIO) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported ZBIO revenue for 2025-12-31 was $10.0M. Net income was -$377.7M. Revenue was up 100.0% from 2024-12-31 to 2025-12-31. ZBIO currently screens at market cap $798.0M.
ZBIO currently screens at market cap $798.0M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new ZBIO 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the ZBIO quote page for the session range and the stock page for the full model.
Not investment advice.